. Author manuscript; available in PMC: 2014 Feb 15.

Published in final edited form as: Cancer. 2012 Sep 12;119(4):871–879. doi: 10.1002/cncr.27816

Table III.

Survival Analysis

			4-year OS		4-year AOS^*			4-year EFS		4-year AEFS^*
		N	OS±SE (%)	p-value	AOS± SE (%)	p-value	N	EFS± SE (%)	p-value	AEFS ±SE (%)	p-value
	Overall	778	40±3		31±2		777	30±3		24±2
Disease Extent	Localized Disease	479	52±3	<0.0001	42±3	<0.0001	479	39±3	<0.0001	33±3	<0.0001
Disease Extent	Metastatic Disease	240	17±4	<0.0001	12±3	<0.0001	239	11±3	<0.0001	8±2	<0.0001
Treatment Era	2000–2004	321	41±3	0.41	30±3	0.92	321	30±3	0.63	23±3	0.93
Treatment Era	2005–2009	457	39±5	0.41	32±4	0.92	456	30±4	0.63	26±4	0.93
Localized Disease, by treatment era	2000–2004	195	56±4	0.13	42±4	0.77	195	41±4	0.27	33±4	0.67
Localized Disease, by treatment era	2005–2009	284	49±6	0.13	42±5	0.77	284	38±5	0.27	33±5	0.67
Diagnosis	Osteosarcoma	262	31±4	0.004^**	23±3	0.0007^**	261	24±4	0.0028^**	19±3	0.0005^**
	Ewing Sarcoma	173	36±6		31±5		172	26±5		23±5
	Rhabdomyosarcoma	238	44±5		34±4		239	33±4		27±4
	Soft-Tissue Sarcoma	105	53±8		42±8		105	43±8		35±7
Disease Location^#	Bone Sarcoma	335	32±4	0.0005	25±3	0.0006	334	23±4	0.0003	20±3	0.0004
	Soft-Tissue Sarcoma	407	46±4	0.0005	36±3	0.0006	407	36±4	0.0003	29±3	0.0004
	Extremity	383	35±4	0.044	28±3	0.0239	381	27±4	0.0727	22±3	0.0376
	Other Location	359	44±4	0.044	35±4	0.0239	360	33±4	0.0727	27±3	0.0376

AOS is abandonment-sensitive overall survival and AEFS is abandonment-sensitive event-free survival (see “Statistical Definitions” in methods for details)

^**

Global test for differences in survival curves across diagnoses. Pairwise analysis done (not shown) to detect individual differences.

Disease Location (see “Subdivision of Data” in methods for details)